H.C. Wainwright reiterates buy rating on Travere Therapeutics stock

Travere Therapeutics (TVTX) shares surged 29% following the FDA's decision to forgo an Advisory Committee meeting for its FILSPARI supplemental New Drug Application (sNDA) in focal segmental glomerulosclerosis (FSGS), signaling regulatory confidence in the drug's data. This positive development, along with eased REMS requirements for FILSPARI in IgA nephropathy, has led multiple analysts, including H.C. Wainwright and Jefferies, to reiterate 'Buy' ratings with price targets up to $47, anticipating a favorable regulatory path towards the January 13, 2026 PDUFA date.

Analysis

Travere Therapeutics (TVTX) has received a significant regulatory de-risking for its drug FILSPARI, acting as a major positive catalyst for the stock. The U.S. FDA's decision to waive the requirement for an Advisory Committee meeting regarding the supplemental New Drug Application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS) has been interpreted by the market and analysts as a strong signal of the agency's confidence in the existing data package. This news, which contributed to a 29% surge in the stock price to $27.31, follows a previous positive development where REMS requirements for FILSPARI in IgA nephropathy were eased. The bullish consensus is reinforced by multiple analyst firms; H.C. Wainwright reiterated its Buy rating with a $47.00 price target, and Jefferies reiterated its Buy rating with a $35.00 price target, both viewing the FDA's move as a significant positive. The sNDA is supported by robust data from the Phase 3 DUPLEX and Phase 2 DUET studies, which demonstrated sustained reductions in proteinuria and a favorable safety profile. With four analysts recently revising earnings estimates upward, the focus now shifts to the PDUFA target action date of January 13, 2026, which remains the key milestone for the FSGS indication.

Key Decisions for Investors

• The FDA's decision to forgo an Advisory Committee meeting significantly de-risks the regulatory path for FILSPARI in FSGS, supporting a bullish outlook for investors with a long-term horizon towards the January 2026 PDUFA date.
• Investors should weigh the substantial upside potential reflected in analyst price targets of $35 to $47 against the stock's recent 29% appreciation, considering whether the positive news is already partially priced in.
• Monitor for any further regulatory communications from the FDA, as these will serve as the primary catalysts for the stock ahead of the final approval decision.
• Recognize that despite the positive signals, the stock's valuation remains heavily dependent on the binary outcome of FILSPARI's final approval, representing a concentrated risk for any position.